ACE-031 Research Protein

Yes. Every batch of ACE-031 is tested by an independent third-party laboratory using HPLC and MS-UPLC, confirming purity and mass identity before the batch is released. Pure Peptides does not test its own material.

It means ACE-031 is supplied for in-vitro laboratory research and for no other purpose, and must not be administered to humans or animals. ACE-031 is legal to purchase in the United States for in vitro and non-clinical laboratory research. It has no FDA approval and no approved human use. ACE-031 is not a scheduled substance under the Controlled Substances Act. Sold strictly for qualified research use, not human or veterinary administration.

ACE-031 ships from US stock with cold-chain packaging and full tracking; orders placed before noon EST on business days are typically dispatched the same business day. On arrival, store the lyophilized powder at -20°C or below, dry and protected from light.

No. ACE-031, international non-proprietary name ramatercept, is a dimeric fusion protein of about 60,000 g/mol. It joins the extracellular ligand-binding domain of the human activin receptor type IIB to the Fc region of human IgG1. It has no CAS registry number, which is expected for a protein of this kind.

A randomised, placebo-controlled trial was stopped after its second dose level. The published report gives the reason as potential safety concerns of epistaxis and telangiectasias, meaning nosebleeds and small dilated blood vessels. The same report states that no serious or severe adverse events occurred and that the efficacy signals it recorded were trends that did not reach statistical significance. The Published Research tab sets out all three findings with the citation.

Fourteen products sold under the ACE-031 name were analysed. Two contained no protein reactive to an ACVR2B antibody. The other twelve contained the full-length human activin receptor IIB rather than the Fc fusion protein the name refers to, which the authors confirmed with a protease that cleaves Fc fusions and could not cleave the products. Published results obtained with characterised ACE-031 are not evidence about material of that kind.

GDF-8, or myostatin, is the ligand: it limits muscle growth. ACE-031 is a soluble decoy receptor that traps it before it reaches the receptor. Follistatin 344 is a binding protein that also binds it. A decoy receptor and a binding protein are different mechanisms, so the three are sold and studied separately and results reported for one are not reported for another.